FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma. Released May 22, 2017

FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma. Released May 22, 2017

FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma. Released May 22, 2017

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

Experts from the U.S. Food and Drug Administration (FDA) discuss important new drug information as well as urgent insights about approved drug products.

Share FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

Sign up to save your podcasts

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma